Belite Bio (BLTE) to Release Earnings on Tuesday

Belite Bio (NASDAQ:BLTE) is scheduled to be announcing its earnings results after the market closes on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.30) per share for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

Belite Bio (NASDAQ:BLTE) last posted its quarterly earnings results on Friday, August 9th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.03). On average, analysts expect Belite Bio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Belite Bio Trading Down 1.6 %

Shares of NASDAQ:BLTE opened at $81.08 on Friday. The firm has a market cap of $2.48 billion, a price-to-earnings ratio of -65.92 and a beta of -1.60. Belite Bio has a 1 year low of $31.00 and a 1 year high of $83.60. The business has a fifty day simple moving average of $55.90 and a 200 day simple moving average of $50.12.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Benchmark reissued a “buy” rating and issued a $57.00 price target on shares of Belite Bio in a research note on Tuesday, August 13th. HC Wainwright reissued a “buy” rating and issued a $60.00 target price on shares of Belite Bio in a research report on Thursday, September 12th.

Belite Bio Company Profile

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company’s lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.